American Cancer Society guideline for the early detection of prostate cancer, 2026
CA: A Cancer Journal for Clinicians · 2026-11 · 76 (6)
DOI: 10.3322/caac.70112 ↗Kurz gefasst
Leitlinie in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 12.11.2026. Verfasst von Richard M Hoffman und 20 weiteren Autor:innen. Beteiligte Einrichtung: University of Iowa Carver College of Medicine, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The goal of prostate cancer screening is to reduce morbidity and mortality through the early detection of clinically significant disease. Accumulating evidence shows that prostate‐specific antigen (PSA)‐based screening significantly reduces prostate cancer mortality and advanced‐stage diagnosis, and approaches to reduce harms associated with screening are increasingly being used. The ACS conducted a systematic review and commissioned a modeling study to evaluate PSA‐based screening strategies, and concluded that the benefits of screening outweigh the harms. Before initiating screening, clinicians should ensure that patients are informed about the benefits, limitations, and harms of screening; the potential follow‐up evaluations of elevated PSA levels; and the expectation that low‐risk cancers will initially be managed with active surveillance. The ACS recommends biennial screening from ages 50‐69 years for average‐risk men (i.e., non‐Black men without a family history of prostate cancer). Annual screening from ages 45‐69 years is recommended for Black men. Annual screening from ages 45–69 years is recommended for non‐Black men with a strong family history (i.e., multiple first‐degree relatives diagnosed with prostate cancer at any age or one diagnosed before age 65 years). Biennial screening from ages 45‐69 years is recommended for non‐Black men with a single first‐degree relative diagnosed at age 65 years or older. For men ages 70–74 years, the balance of benefits and harms is uncertain, and individualized decision making is recommended. The ACS recommends further evaluating men ages 45–69 years with PSA levels ≥3.0 ng/mL and men ages 70–74 years with PSA levels ≥6.5 ng/mL. Most men who have elevated PSA levels confirmed on repeat testing should be offered magnetic resonance imaging and/or a validated biomarker test to guide biopsy decisions. Screening is not recommended for men with a life expectancy
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
- University of Virginia School of Medicine, Charlottesville, Virginia, USA.
- Biostatistics Program, Fred Hutch Cancer Center, Seattle, Washington, USA.
- Duke Cancer Institute Center for Onco-Primary Care, Duke University, Durham, North Carolina, USA.
- Radiation Oncology, Brown University Health, Brown School of Public Health, Providence, Rhode Island, USA.
- Biostatistics, Brown School of Public Health, Providence, Rhode Island, USA.
ORCID-Profile: Richard M Hoffman, Andrew M D Wolf, Ruth D Etzioni, Kevin C Oeffinger, Sana Raoof, Louise C Walter, Charnita Zeigler-Johnson, Timothy R Church, Artie L Shelton, Elena B Elkin, Carmen E Guerra, Rebecca B Perkins, Ya-Chen Tina Shih, Steven J Skates, Roman Gulati, Hormuzd A Katki, Tyler B Kratzer, Deana Manassaram-Baptiste, William L Dahut, Robert A Smith
Zitieren
APA
Hoffman, R. M., Wolf, A. M. D., Etzioni, R. D., Oeffinger, K. C., Raoof, S., Walter, L. C., Zeigler-Johnson, C., Church, T. R., Jones, C. K., Shelton, A. L., Elkin, E. B., Guerra, C. E., Perkins, R. B., Shih, Y. T., Skates, S. J., Gulati, R., Katki, H. A., Kratzer, T. B., Manassaram-Baptiste, D., …, & Smith, R. A. (2026). American Cancer Society guideline for the early detection of prostate cancer, 2026. CA: A Cancer Journal for Clinicians, 76(6). https://doi.org/10.3322/caac.70112
Vancouver
Hoffman RM, Wolf AMD, Etzioni RD, Oeffinger KC, Raoof S, Walter LC, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA: A Cancer Journal for Clinicians. 2026;76(6). doi:10.3322/caac.70112
BibTeX
@article{Hoffman2026,
author = {Hoffman, Richard M and Wolf, Andrew M D and Etzioni, Ruth D and Oeffinger, Kevin C and Raoof, Sana and Walter, Louise C and Zeigler-Johnson, Charnita and Church, Timothy R and Jones, Christopher K and Shelton, Artie L and Elkin, Elena B and Guerra, Carmen E and Perkins, Rebecca B and Shih, Ya-Chen Tina and Skates, Steven J and Gulati, Roman and Katki, Hormuzd A and Kratzer, Tyler B and Manassaram-Baptiste, Deana and Dahut, William L and Smith, Robert A},
title = {American Cancer Society guideline for the early detection of prostate cancer, 2026},
journal = {CA: A Cancer Journal for Clinicians},
year = {2026},
volume = {76},
number = {6},
doi = {10.3322/caac.70112}
}
EUVIMED